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A study of 568 children aged !5 years who commenced non-
nucleoside reverse-transcriptase inhibitor–based antiretro-
viral therapy in resource-limited settings revealed good early
outcomes. After 12 months of antiretroviral therapy,survival
probability was 0.89 (95% conﬁdence interval, 0.86–0.92),
with no signiﬁcant difference among children stratiﬁed on
the basis of baseline immunological levels; 62% attained a
CD4 cell percentage 125%, and 7% continued to have a CD4
cell percentage !15%.
Antiretroviral therapy (ART) substantially reduces HIV-related
mortality and morbidity in children living in resource-rich set-
tings [1]. Despite large numbers of children in urgent need [2]
and high mortality rates among children who do not receive
treatment [3], in resource-limited settings,veryfewchildrenhave
had access to ART. Although the limited available data suggest
good early outcomes amongchildrenreceivingART,thesestudies
involve only small numbers of young children [4, 5].
The World Health Organization (WHO) [6] guidelines rec-
ommend initiating ART in all children with a CD4 cell per-
centage !15%, regardless of their clinical status. This is based
on observational data from cohorts of children in resource-
rich settings where those with a CD4 cell percentage !15% had
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a higher risk of progression to AIDS or death, compared with
those with a CD4 cell percentage 15% [7].
We performed a retrospective analysis of program data from
resource-limited settings in 14 countries to report treatment
outcomes among young children (age, 18–59 months) with
severe or profound immunosuppression on the basis of CD4
cell percentage criteria at the time of commencement of non-
nucleoside reverse-transcriptase inhibitor–based ART and to
compare these outcomes with those of children with mild-to-
moderate immunosuppression.
Patients and methods. We analyzedinformationfromchil-
dren registered during April 2002–May 2006 in 26 Me ´decins
Sans Frontie `res HIV/AIDS programs in 14 countries, including
10 in Africa (Benin, Burkina Faso, Democratic Republic of
Congo, Kenya, Malawi, Mozambique, Nigeria, Uganda, Zam-
bia, and Zimbabwe) and 4 in Asia (Cambodia, Laos, China,
and Myanmar). Eligible children were aged 18–59 months and
had a recorded CD4 cell percentage at the time of ART initi-
ation. Children were recruited from programs with5children
receiving ART and initiated ART 16 months prior to the anal-
ysis. HIV/AIDS care was provided for free, with medical doc-
tors, clinical ofﬁcers, or nurses performing the consultations.
The level of immunosuppression was deﬁned by the CD4
cell percentage level prior to initiation of ART (baseline) and
was categorized as profound (!5%), severe (5% to !15%),
or mild to moderate (15%). Depending on program con-
ditions, CD4 cell percentage was calculated using either au-
tomated or manual methods, with quality control in place. We
calculated the change in CD4 cell percentage as the difference
between baseline and 12-month measurements for the same
child.
All HIV-positive children who met the standard WHO clin-
ical and immunological criteria for starting ART in children
were considered eligible to receive ART [8] and initiated ART
using standard WHO ﬁrst-line regimens administered as syr-
ups, single molecules, or as adult, generic ﬁxed-dose combi-
nation tablets (Triviro [Ranbaxy]) cut in half [9]. Childrenwere
routinely prescribed trimethoprim-sulfamethoxazole prophy-
laxis according to WHO/UNAIDS guidelines [10]. Antiretro-
viral naive was deﬁned as no previous antiretroviral exposure,
including through prevention of mother-to-child transmission
interventions.
Data collection in each of the programs was performedusing
a standardized data collection form, and data were entered into
the Fuchia software (Epicentre-MSF). Datasetswerepooledand
analyzed using Stata software, version 9.2 (Stata). The char-1246 • CID 2007:44 (1 May) • HIV/AIDS
Table 1. Characteristics at antiretroviral therapy initiation among children stratiﬁed on the basis of CD4 cell percentage.
Characteristic
Baseline CD4 cell percentage
(n p 586)
P !5% 5% to !15% 15%
No. (%) of total patients 93 (16) 372 (63) 121 (21)
Median CD4 cell percentage (IQR) 2.5 (1.2–4.0) 10.3 (8.0–12.4) 18.7 (16.0–24.8)
African 67 (72) 307 (83) 99 (82) .07
Asian 26 (28) 65 (18) 22 (18)
Female sex 38 (41) 172 (46) 55 (46) .6
Age, median years (IQR) 3.8 (3.0–4.4) 3.1 (2.4–4.1) 3.1 (2.4–4.0) !.001
Weight, median kg (IQR) 11 (9.3–13.0) 12 (10–14) 12 (9.5–14) .63
Proportion of patients with less than 2 weight-height Z score (%) 12/45 (27) 24/194 (12) 12/73 (16) .06
Proportion of patients with CDC stage C (%) 39/83 (47) 143/338 (42) 44/115 (38) .47
ARV naive 90 (97) 365 (98) 114 (94) .08
Received EFV-based regimen at initiation 23 (25) 31 (8) 6 (5) !.001
Received AZT-based regimen at initiation 27 (29) 86 (23) 41 (34) .06
NOTE. Data are no. (%) of patients, unless otherwise indicated. ARV, antiretroviral; AZT, zidovudine; CDC, Centers for Disease Control and Prevention; EFV,
efavirenz; IQR, interquartile range.
acteristics of patients at initiation of ART according to im-
munosuppression group were compared using a x
2 test for
categorical variables and a t test or Kruskal-Wallis test for con-
tinuous variables. Probabilities of survival after initiation of
ART were determined using the Kaplan Meier method (with
the combined end point of death or loss to follow-up) and
compared using the log rank test.
Results. Five hundred eighty-six children were included in
the analysis: 93 (16%) had profound, 372 (63%) had severe,
and 121 (21%) had mild-to-moderate baseline immunosup-
pression. Five hundred sixty-nine children (97%) were anti-
retroviral naive at ART initiation. Characteristics at ART base-
line were similar in all categoriesofimmunosuppression,except
for median age ( ) and ART regimen (efavirenz-based; P ! .001
) (table 1). P ! .001
Three hundred eighty-eight children (66%) commenced a
regimen of stavudine, lamivudine, and nevirapine; 135 (23%)
received zidovudine, lamivudine, and nevirapine; 40 (7%) re-
ceived stavudine, lamivudine, and efavirenz; 18 (3%) received
zidovudine, lamivudine, and efavirenz; and 5 (!1%) received
another regimen. The median duration of administration of
ART was 13.9 months (interquartile range [IQR], 7.2–19.7
months), with no signiﬁcant difference among the groups. At
analysis, 470 children (80%) were alive and receiving ART, 34
(6%) were dead, 10 (2%) stopped ART, 47 (8%) were lost to
follow-up, 21 (4%) transferred out of the program, and 4 (1%)
had unknown outcomes.
The overall probability of survival (death plus loss to follow-
up) at 6, 12, and 24 months was 0.92 (95% CI, 0.90–0.94),
0.89 (95% CI, 0.86–0.92), and 0.82 (95% CI, 0.78–0.86), re-
spectively. There were no statistically signiﬁcant differences
among the groups ( ), even after adjusting for baseline P p .15
age, sex, Centers for Disease Control and Prevention status,
previous ART exposure, acute malnutrition, geographical con-
tinent, and ART regimen (table 2). Twenty-six (76%) of 34
deaths occurred within 6 months of commencement of ART
(median, 1.4 months; IQR, 0.6–5.6 months). No children were
given second-line ART regimens.
After 12 months of receiving ART, 180 (53%) of 338 eligible
children had a recorded CD4 cell percentage result. Among
these children, the median CD4 cell percentage gain was 18%
for those with profound immunosuppression, 16% for those
with severe immunosuppression, and 12% for those with mild-
to-moderate immunosuppression ( ). Only 21% of P p .007
children in the profound immunosuppression group and 6%
in the severe immunosuppression group had a CD4 cell per-
centage !15% (ongoing severe immunosuppression), and close
to normal levels of immune function (CD4 cell percentage,
125%) were achieved for 32% of children in the profound
immunosuppression group, 63% in the severe immunosup-
pression group, and 82% in the mild-to-moderate immuno-
suppression group (112 children [62%] overall). Baseline char-
acteristics of those with and without CD4 cell percentage data
at 12 months were similar, except that 28% of the former group
were from Asia, compared with 10% in the latter group (P !
). .001
Discussion. Despite the fact that the great majority of chil-
dren starting ART in this study were severely immunosup-
pressed (79%), 8 of 10 children were still alive after 2 years of
therapy. Such survival rates are similar to thosereportedamong
adults [11] and a small cohort of older children in resource-
limited settings [5], and the rates are in sharp contrast to the
very high short-term mortality rates reported among similar
children in resource-limited settings who are not receivingARTHIV/AIDS • CID 2007:44 (1 May) • 1247
Table 2. Outcomes of antiretroviral therapy (ART) among children stratiﬁed on the basis of CD4 cell percentage
at baseline.
Characteristic
CD4 cell percentage
P !5% 5% to !15% 15%
Probability of length of survival
6 months
Probability (95% CI) 0.85 (0.76–0.91) 0.94 (0.91–0.96) 0.92 (0.86–0.96) .15
No. of patients 74 326 100
12 months
Probability (95% CI) 0.83 (0.74–0.90) 0.91 (0.87–0.93) 0.90 (0.83–0.94)
No. of patients 57 215 71
24 months
Probability (95% CI) 0.80 (0.69–0.87) 0.82 (0.75–0.87) 0.86 (0.76–0.92)
No. of patients 15 55 14
Median CD4 cell percentage after 12 months of ART (IQR) 20.4 (15.5–30.0) 27.0 (22.0–32.0) 33.0 (27.0–39.0) !.001
Median CD4 cell percentage increase (IQR) 17.5 (13.8–27.2) 16.0 (11.0–22.6) 12.3 (5.3–18.1) .007
No. of patients with CD4 cell percentage !15%
after 12 months (%) 6 (21) 7 (6) 2 (5) .005
No. of patients with CD4 cell percentage 125%
after 12 months (%) 9 (32) 71 (63) 32 (82) !.001
Proportion of patients with less than 2 weight-height Z score
after 12 months (%) 0/23 (0) 1/78 (1) 1/31 (3) .61
NOTE. Data for CD4 cell percentage are for 28 children with a CD4 cell percentage !5%, 113 with a CD4 cell percentage 5%
to !15%, and 39 with a CD4 cell percentage 15%. IQR, interquartile range.
[3]. Compared with survival rates among children with mild-
to-moderate immunosuppression (CD4 cell percentage,
15%), survival rates inthose withsevere(CD4cellpercentage,
5% to !15%) and profound (CD4 cell percentage, !5%)
immunosuppression were similar, despite signiﬁcantly higher
mortality rates without receipt of ART [7]. However, our data
suggest that rates might be lower for the profoundly immu-
nosuppressed group, and this warrants further assessment with
a larger sample size.
Likewise, the immunological outcomes that resulted from
receiving ART were good, with evidence of signiﬁcant immu-
nological reconstitution in the majority of the cohort. After 1
year of receiving ART, 62% of children with an available CD4
cell percentage attained near normal immune status (CD4 cell
percentage, 125%) [12], and only 7% remained at signiﬁcant
risk of life-threatening opportunistic infections ordisease(CD4
cell percentage, !15%) [12]. Those with profound immuno-
suppression had the greatest absolute median increases in CD4
cell percentage, but they attained lower median absolute CD4
cell percentage levels, and a signiﬁcantly higher proportion re-
mained severely immunosuppressed. This suggests that, al-
though signiﬁcant improvements in immune function occur
irrespective of baseline CD4 cell percentage levels, the greater
the level of baseline immunodeﬁciency, the more likely the
patient will remain at risk of opportunistic infections during
the ﬁrst year of receiving ART.
To our knowledge, therearenosimilarstudiesfromresource-
limited settings analyzing immunologicaloutcomesonthebasis
of baseline CD4 cell percentage levels in young children. How-
ever, our results were similar to those published from resource-
rich settings [1, 12]—although the children from resource-rich
settings were mainly ART nonnaive, had mean ages 16 years,
were less immunosuppressed (i.e., the CD4 cell percentage was
!15% for 33%–54% of the cohorts), and were treated with
mainly protease inhibitor–containing regimens.
Although overall outcomes were good, our ﬁndings suggest
that better outcomes are achieved if ART is started before pro-
found immunosuppression develops. Measures needed to
achieve this include increased access to and offer of HIV testing
to ensure early diagnosis of HIV, increased access to CD4 T
cell testing methods to identify severely immunosuppressed
children before they develop opportunistic infections, greater
education of parents and health care workers regarding the
beneﬁts of ART for children to encourage earlier presentation
to health services, and increased availability of adapted and
affordable pediatric medications to makeinitiationoftreatment
possible and less complex.
There are a number of study limitations. First, because of
the operational constraints of resource-limited settings, most
programs had no access to viral load measurements.Therefore,
despite the good early survival and immunological outcomes,
we cannot exclude the possibility of suboptimalvirologicalsup-
pression resulting in less satisfactory longer-term outcomes.
Secondly, we had incomplete data on immunologicaloutcomes1248 • CID 2007:44 (1 May) • HIV/AIDS
(53% of children had an available CD4 cell percentage at 12
months). This was likely a result of operational constraints in
providing CD4 measurements. However, apart from regional
differences, the ART baseline characteristics did not differ sig-
niﬁcantly between those with and without CD4 cell percentage
data at 12 months. Thus, we feel that the population with
available CD4 immunological outcomes was representative of
the overall cohort population. Nevertheless, it is possible that
the reported immunological gains were overestimated, because
they only consider surviving children and those not lost to
follow-up. Thirdly, we do not have ART adherence data to
exclude differences in adherence rates among the groups, po-
tentially inﬂuencing outcomes. Finally, our cohort represents
only children with a known baseline CD4 cell percentage, and
because this may have introduced a selection bias, our ﬁndings
may not be generalizable to a cohort of children in resource-
limited settings where baseline CD4 cell percentage is not
known.
This study demonstrates that in resource-limited settings,
under routine program conditions, administration of nonnu-
cleoside reverse-transcriptase inhibitor–containing ART to se-
verely and profoundly immunosuppressed children canachieve
good early outcomes, and these outcomes are comparable to
results among mild-to-moderately immunosuppressed chil-
dren. This provides further impetus to urgently ensure that
children in resource-limited settings have early access to life-
prolonging ART.
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